IQVIA Holdings (IQV) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and IQVIA published the results on October 27, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. IQVIA reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted Diluted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• From January 1, 2026 IQVIA reports two segments, Commercial Solutions and Research & Development Solutions, in place of three. Prior-period segment figures are IQVIA's recast amounts.
• IQVIA cut its R&DS contracted backlog by about $2.1 billion after reviewing inactive trials. It says the adjustment has no impact on historical results, 2026 guidance, book-to-bill or next-twelve-month revenue from backlog estimates.

Source: IQVIA Q3 2026 results, October 27, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How IQVIA splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• IQVIA's Commercial Solutions revenue was $1.8 billion in Q3 2026, up 7% from $1.7 billion in Q3 2025, 40% of total revenue.
• IQVIA's Research & Development Solutions revenue was $2.6 billion in Q3 2026, up 9% from $2.4 billion in Q3 2025, 60% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, IQVIA said:

“The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 million and for Adjusted Diluted Earnings per Share to be between $12.90 and $13.00.”

“This revenue guidance now anticipates 250 basis points of contribution from acquisitions, including acquisitions the company expects to complete by the end of the year, and approximately 20 basis points of tailwind from foreign exchange.”

“All financial guidance assumes foreign currency exchange rates as of October 26, 2026 remain in effect for the forecast period.”

Source: IQVIA Q3 2026 release, Oct 27, 2026.

This is the company's own guidance as of Oct 27, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the IQV forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenues and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for IQVIA's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 27, 2026

IQVIA's Q3 2026 revenue of $4,428 million came from two segments. Research & Development Solutions, its clinical research business, brought in $2,639 million, up 8.7%, and Commercial Solutions $1,789 million, up 6.9%. Total revenue rose 8.0% as reported and 8.6% at constant currency. (IQVIA Q3 2026 earnings release, Oct 27, 2026)

R&DS revenue includes reimbursed expenses; excluding them, IQVIA says R&DS revenue grew 6.8%. Net new bookings were $3.2 billion, up 15%, a book-to-bill ratio of 1.2x, and contracted backlog was $32.6 billion, of which IQVIA expects about $9.4 billion to convert to revenue in the next twelve months. (IQVIA Q3 2026 earnings release, Oct 27, 2026)

IQVIA attributes Commercial Solutions growth mainly to patient solutions (formerly in real-world solutions) and to a lesser extent commercial engagement services (formerly contract sales and medical solutions), with growth led by the Americas. R&DS growth came mainly from Europe and Africa and the Americas. (IQVIA Form 10-Q, Q3 2026, Oct 27, 2026)

By geography, the Americas produced $2,087 million of Q3 2026 revenue, Europe and Africa $1,417 million and Asia-Pacific $924 million. Asia-Pacific is mostly clinical: $707 million of it was R&DS. No single customer represented 10% or more of consolidated revenues. (IQVIA Form 10-Q, Q3 2026, Oct 27, 2026)

IQVIA's GAAP diluted EPS was $2.10 in Q3 2026 against Adjusted Diluted EPS of $3.34. The biggest adjustment was $163 million of purchase accounting amortization, which IQVIA excludes in full from adjusted results, followed by $83 million of stock-based compensation and $41 million of restructuring and related expenses. GAAP net income was $350 million and Adjusted Net Income $557 million. (IQVIA Q3 2026 earnings release, Oct 27, 2026)

IQVIA's share count fell. Diluted weighted average shares fell to 167.0 million from 171.7 million, and IQVIA repurchased 5.5 million shares for $950 million in the first nine months of 2026, with $2,819 million of authorization left at September 30. (IQVIA Q3 2026 earnings release, Oct 27, 2026; IQVIA Form 10-Q, Q3 2026, Oct 27, 2026)

IQVIA's effective income tax rate was 19.7% against 18.6% a year earlier, which it attributes to changes in the geographic mix of earnings. Interest expense rose to $203 million from $189 million, and debt stood at $16,067 million at quarter end. (IQVIA Form 10-Q, Q3 2026, Oct 27, 2026; IQVIA Q3 2026 earnings release, Oct 27, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

IQVIA gives full-year guidance in each release. With Q3 2026 it raised its 2026 range to revenue of $17,350 million to $17,500 million, Adjusted EBITDA of $4,025 million to $4,055 million and Adjusted Diluted EPS of $12.90 to $13.00. The revenue range includes 250 basis points from acquisitions and about 20 basis points of foreign exchange tailwind, at exchange rates as of October 26, 2026. (IQVIA Q3 2026 earnings release, Oct 27, 2026)

IQVIA said it will hold an Investor Day on December 1, 2026. Through the first nine months, revenue was $12,947 million and Adjusted Diluted EPS $9.38. (IQVIA Q3 2026 earnings release, Oct 27, 2026)

A consensus figure is the average of the models published by the analysts who cover IQVIA, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones IQVIA's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning IQV is on is IQV a buy or a sell?, what analysts expect next is on the IQV forecast, and what the company does is on the IQVIA Holdings (IQV) stock page.

Every number on this page can be traced to a document IQVIA published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.